|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i>, anti-CD30-MCC-DM1 was found to be capable of inducing tumor regression in subcutaneous inoculation of Karpas 299 (anaplastic large cell lymphoma), HH (cutaneous T-cell lymphoma) and L428 (Hodgkin's disease) cell models.
|
31161871 |
2020 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 is promising target as it is universally expressed in virtually all classical Hodgkin lymphomas, anaplastic large cell lymphomas, and in a proportion of other lymphoma types, including cutaneous T cell lymphomas and diffuse large B cell lymphomas.
|
30841880 |
2019 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells, the malignant cells in HL.
|
31616638 |
2019 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hodgkin's lymphoma (HL) has a unique immunophenotype derived from immunohistochemistry (positive for CD15, CD30, and Pax-5; negative for CD3, CD20 in most cases, and CD45).
|
30350336 |
2019 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 is expressed on a variety of B-cell lymphomas, such as Hodgkin lymphoma, primary effusion lymphoma, and a diffuse large B-cell lymphoma subgroup.
|
30962205 |
2019 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma.
|
30140037 |
2019 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
|
31476851 |
2019 |
|
Adult Hodgkin Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma.
|
30140037 |
2019 |
|
Adult Hodgkin Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hodgkin's lymphoma (HL) has a unique immunophenotype derived from immunohistochemistry (positive for CD15, CD30, and Pax-5; negative for CD3, CD20 in most cases, and CD45).
|
30350336 |
2019 |
|
Adult Hodgkin Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD30 is expressed on a variety of B-cell lymphomas, such as Hodgkin lymphoma, primary effusion lymphoma, and a diffuse large B-cell lymphoma subgroup.
|
30962205 |
2019 |
|
Adult Hodgkin Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells, the malignant cells in HL.
|
31616638 |
2019 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
|
29390984 |
2018 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Following a wedge resection, histopathological examination showed Reed-Sternberg cells that were positive for CD-15 and CD-30, which is typical of HL.
|
29742695 |
2018 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Their specific features and relationship to CD30-expressing Hodgkin and Reed/Sternberg (HRS) cells of Hodgkin lymphoma are unclear but highly relevant, because numerous patients with lymphoma are currently treated with an anti-CD30 immunotoxin.
|
29889102 |
2018 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas broadly segregated into ALK-positive and ALK-negative types.
|
30093402 |
2018 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is an anti-CD30 monoclonal antibody which has been proven to be a safe and effective therapeutic agent in the treatment of CD30-positive lymphomas, such as Hodgkin lymphoma and ALCL.
|
29806104 |
2018 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is a Food and Drug Administration approved anti-CD30 antibody drug conjugate potently active in Hodgkin lymphoma.
|
29280762 |
2018 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL).
|
29316337 |
2018 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin (BV) is a second-generation antibody-drug conjugate (ADC) constituted by an anti-CD30 antibody linked to the cytotoxic drug monomethyl auristatin E. The first administration of BV in relapsed and refractory HL patients in a phase I study showed an impressive antilymphoma activity and prompted development of the drug.
|
29999431 |
2018 |
|
Adult Hodgkin Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is a Food and Drug Administration approved anti-CD30 antibody drug conjugate potently active in Hodgkin lymphoma.
|
29280762 |
2018 |
|
Adult Hodgkin Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Their specific features and relationship to CD30-expressing Hodgkin and Reed/Sternberg (HRS) cells of Hodgkin lymphoma are unclear but highly relevant, because numerous patients with lymphoma are currently treated with an anti-CD30 immunotoxin.
|
29889102 |
2018 |
|
Adult Hodgkin Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
|
29390984 |
2018 |
|
Adult Hodgkin Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Following a wedge resection, histopathological examination showed Reed-Sternberg cells that were positive for CD-15 and CD-30, which is typical of HL.
|
29742695 |
2018 |
|
Adult Hodgkin Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL).
|
29316337 |
2018 |
|
Adult Hodgkin Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is an anti-CD30 monoclonal antibody which has been proven to be a safe and effective therapeutic agent in the treatment of CD30-positive lymphomas, such as Hodgkin lymphoma and ALCL.
|
29806104 |
2018 |